Exchange Protein Directly Activated by cAMP 2 Enhances Respiratory Syncytial Virus-Induced Pulmonary Disease in Mice

Exchange Protein Directly Activated by cAMP 2 Enhances Respiratory Syncytial Virus-Induced Pulmonary Disease in Mice

Blog Article

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in young children.It is also a significant contributor to upper respiratory tract infections, therefore, a major cause for visits to the pediatrician.High keychron m4 morbidity and mortality are associated with high-risk populations including premature infants, the elderly, and the immunocompromised.However, no effective and specific treatment is available.Recently, we discovered that an exchange protein directly activated by cyclic AMP 2 (EPAC2) can serve as a potential therapeutic target for RSV.

In both lower and upper epithelial cells, EPAC2 promotes RSV replication and pro-inflammatory cytokine/chemokine induction.However, the overall role of EPAC2 in the pulmonary responses to RSV has not been investigated.Herein, we found that EPAC2-deficient mice (KO) or mice treated with an EPAC2-specific inhibitor showed a significant decrease in body weight loss, airway hyperresponsiveness, and pulmonary inflammation, compared with wild-type (WT) or vehicle-treated mice.Overall, this study demonstrates the critical contribution of the EPAC2-mediated pathway to airway diseases in experimental click here RSV infection, suggesting the possibility to target EPAC2 as a promising treatment modality for RSV.